Security
XOMAO · XOMA Royalty Corp
XOMAONASDAQPreferred stockHistorical · closed Jul 13, 2026CIK 791908Updated Sep 26, 2026
Name history
XOMA Corp · through Jul 9, 2024XOMA LTD /DE/ · through Jan 17, 2012XOMA CORP /DE/ · through Mar 19, 1998
XOMAO price & chart
Historical security
This listing closed Jul 13, 2026. Live provider charts are shown only for current listings.
About the company
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. XOMA Royalty has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about XOMA Royalty and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.
In the news
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 272,698,000Source | 221,277,000Source | 234,301,000Source | 140,382,000Source |
| Property, Plant and Equipment, NetUSD | 21,000Source | 32,000Source | 25,000Source | 7,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 44,756,000Source | 25,909,000Source | — | 15,150,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 82,908,000Source | 101,654,000Source | 153,290,000Source | 57,826,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | — | 0Source |
| Assets, CurrentUSD | 117,259,000Source | 125,604,000Source | 169,313,000Source | 61,253,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 852,000Source | 2,076,000Source | 483,000Source | 725,000Source |
| Operating Lease, Right-of-Use AssetUSD | 256,000Source | 319,000Source | 378,000Source | 29,000Source |
| Other Assets, NoncurrentUSD | 427,000Source | 1,861,000Source | 533,000Source | 260,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 168,738,000Source | 139,356,000Source | 145,580,000Source | 16,368,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 89,000Source | 90,000Source | 86,000Source | 86,000Source |
| Additional Paid in CapitalUSD | 1,305,200,000Source | 1,318,766,000Source | 1,311,809,000Source | 1,306,271,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,221,450,000Source | -1,237,057,000Source | -1,223,223,000Source | -1,182,392,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 53,000Source | 73,000Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | 83,941,000Source | 81,921,000Source | 88,721,000Source | 124,014,000Source |
| Liabilities and EquityUSD | 272,698,000Source | 221,277,000Source | 234,301,000Source | 140,382,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 34,820,000Source | 24,374,000Source | 19,499,000Source | 6,818,000Source |
| Operating Lease, Liability, CurrentUSD | 2,464,000Source | 446,000Source | 54,000Source | 34,000Source |
| Accounts Payable, CurrentUSD | 2,208,000Source | 1,053,000Source | 653,000Source | 524,000Source |
| Operating Lease, Liability, NoncurrentUSD | 20,114,000Source | 483,000Source | 335,000Source | — |
| Deferred Income Tax Liabilities, NetUSD | 103,000Source | 5,684,000Source | — | — |
| Additional Financial Items | ||||
| Deferred Tax Liabilities, NetUSD | 0Source | — | — | — |
| Dividends PayableUSD | 1,424,000Source | 1,368,000Source | 1,368,000Source | 1,368,000Source |
| Long-term Debt, Current MaturitiesUSD | 12,526,000Source | 11,394,000Source | 5,543,000Source | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 96,451,000Source | 106,875,000Source | 118,518,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | 31,712,000Source | -13,821,000Source | -40,831,000Source | -17,104,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 9,273,000Source | 10,312,000Source | 9,099,000Source | 3,608,000Source |
| Deferred Income Tax Expense (Benefit)USD | 103,000Source | -5,658,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 2,871,000Source | -13,748,000Source | -18,158,000Source | -12,879,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 50,886,000Source | -28,259,000Source | -711,000Source | -20,221,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | 20,000Source | 17,000Source | — |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 2,986,000Source | 3,214,000Source | 148,000Source | 1,398,000Source |
| Payments for Repurchase of Common StockUSD | 16,043,000Source | 13,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -26,463,000Source | -11,127,000Source | 120,593,000Source | -4,451,000Source |
| Dividends paid | — | — | — | — |
| Repayments of Long-term DebtUSD | 10,598,000Source | 6,902,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 27,294,000Source | -53,134,000Source | 101,724,000Source | -37,551,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 133,710,000Source | 106,416,000Source | 159,550,000Source | 57,826,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 11,906,000Source | 9,985,000Source | — | — |
| Income Taxes Paid, NetUSD | 277,000Source | — | — | 76,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | 10,312,000Source | — | — |
| Amortization of Debt Issuance Costs and DiscountsUSD | 1,385,000Source | 1,350,000Source | 34,000Source | — |
| Amortization of Intangible AssetsUSD | 2,961,000Source | 206,000Source | 897,000Source | 97,000Source |
| Depreciation, NonproductionUSD | 11,000Source | 10,000Source | 3,000Source | 7,000Source |
| Dividends PayableUSD | 1,424,000Source | 1,368,000Source | 1,368,000Source | 1,368,000Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | 3,663,000Source | 131,000Source | -174,000Source | -439,000Source |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | 90,000Source | — | — | — |
| General and Administrative ExpenseUSD | 36,092,000Source | 34,478,000Source | 25,606,000Source | 23,191,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | 14,253,000Source | — |
| Income Tax Expense (Benefit)USD | 103,000Source | -5,658,000Source | 0Source | -15,000Source |
| Net Income (Loss) Attributable to ParentUSD | 31,712,000Source | -13,821,000Source | -40,831,000Source | -17,104,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 18,516,000Source | -19,293,000Source | -46,303,000Source | -22,576,000Source |
| Operating ExpensesUSD | 40,765,000Source | 68,463,000Source | 46,606,000Source | 23,441,000Source |
| Other Nonoperating Income (Expense)USD | 12,238,000Source | 6,921,000Source | 1,586,000Source | 295,000Source |
| Payments of Financing CostsUSD | — | 740,000Source | 4,253,000Source | — |
| Proceeds from Issuance of Common StockUSD | 323,000Source | — | — | — |
| Proceeds from Issuance of Long-term DebtUSD | — | — | 130,000,000Source | — |
| Unrealized Gain (Loss) on DerivativesUSD | 93,000Source | — | — | — |
| Unrealized Gain (Loss) on InvestmentsUSD | 3,470,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | — | 2,650,000Source | 4,150,000Source |
| Operating Income (Loss)USD | 11,384,000Source | -39,976,000Source | -41,848,000Source | -17,414,000Source |
| Other Nonoperating Income (Expense)USD | 12,238,000Source | 6,921,000Source | 1,586,000Source | 295,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 31,815,000Source | -19,479,000Source | -40,831,000Source | -17,119,000Source |
| Income Tax Expense (Benefit)USD | 103,000Source | -5,658,000Source | 0Source | -15,000Source |
| Net Income (Loss) Attributable to ParentUSD | 31,712,000Source | -13,821,000Source | -40,831,000Source | -17,104,000Source |
| Earnings Per Share, BasicUSD per share | 1.53Source | -1.65Source | -4.04Source | -1.98Source |
| Earnings Per Share, DilutedUSD per share | 1.46Source | -1.65Source | -4.04Source | -1.98Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 12,081,000Source | 11,701,000Source | 11,471Source | 11,413,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 17,982,000Source | 11,701,000Source | 11,471Source | 11,413,000Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 2,961,000Source | 206,000Source | 897,000Source | 97,000Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | 3,663,000Source | 131,000Source | -174,000Source | -439,000Source |
| General and Administrative ExpenseUSD | 36,092,000Source | 34,478,000Source | 25,606,000Source | 23,191,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 32,032,000Source | — | — | — |
| Interest Expense, DebtUSD | 13,031,000Source | 13,840,000Source | 569,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 18,516,000Source | -19,293,000Source | -46,303,000Source | -22,576,000Source |
| Operating ExpensesUSD | 40,765,000Source | 68,463,000Source | 46,606,000Source | 23,441,000Source |
| Research and Development ExpenseUSD | 1,712,000Source | 2,875,000Source | 143,000Source | 153,000Source |
| Undistributed Earnings (Loss) Allocated to Participating Securities, BasicUSD | 7,668,000Source | — | — | — |
Filing attachments
d165297dex991.htm · 8-K · 2026-07-14
EX-99.1 2 d165297dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 XOMA Royalty Announces Closing of Its Acquisition by Ligand EMERYVILLE, Calif., July 14, 2026 - XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has completed its previously announced acquisition of XOMA Royalty. Pursuant to the terms of the transaction announced on April 27, 2026, Ligand acquired all of the outstanding shares of XOMA Royalty common stock. XOMA Royalty stockholders re…
Read attachment ↗d143305dex991.htm · 8-K · 2026-06-12
EX-99.1 2 d143305dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE June 12, 2026 XOMA ROYALTY CORPORATION DECLARES QUARTERLY PREFERRED STOCK DIVIDEND AND ANNOUNCES REDEMPTION OF ITS PERPETUAL PREFERRED STOCK AND CVR DIVIDEND RECORD DATE Emeryville, CA - June 12, 2026 - XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced that its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s (i) 8.625% Series A Cumu…
Read attachment ↗d139894dex991.htm · 8-K · 2026-04-27
EX-99.1 4 d139894dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator Transaction expands Ligand’s royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand’s long-term compounding growth, adding a complementary portfolio across development stages, therapeutic areas, and modalities to broaden patient acc…
Read attachment ↗d34671dex991.htm · 8-K · 2026-03-18
EX-99.1 2 d34671dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements Portfolio receipts: • Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones, in full year 2025 • Total receipts increased 9% with royalties up 68% versus full year 2024 Business development: Added 22 assets to portfolio, including five programs in Phase 2 or Phase 3 development Stock buyba…
Read attachment ↗d34671dex992.htm · 8-K · 2026-03-18
EX-99.2 3 d34671dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 CORPORATE PRESENTATION THE ROYALTY AGGREGATOR NASDAQ COMMON: XOMA FOR BIOTECH NASDAQ PERPETUAL PREFERRED SHARES: XOMAP, XOMAO COMPANIES Q1 2026 DISCLAIMERS Certain statements in this presentation are forward-looking statements 10-K and Form 10-Q. Consider such risks carefully when considering within the meaning of Section 27A of the Securities Act of 1933 and XOMA Royalty's prospects. Any forward-looking statements represent Section 2…
Read attachment ↗d112965dex991.htm · 8-K · 2026-03-02
EX-99.1 2 d112965dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 CORPORATE PRESENTATION THE ROYALTY AGGREGATOR NASDAQ COMMON: XOMA FOR BIOTECH NASDAQ PERPETUAL PREFERRED SHARES: XOMAP, XOMAO COMPANIES Q1 2026 DISCLAIMERS Certain statements in this presentation are forward-looking statements 10-K and Form 10-Q. Consider such risks carefully when considering within the meaning of Section 27A of the Securities Act of 1933 and XOMA Royalty's prospects. Any forward-looking statements represent Section …
Read attachment ↗